Literature DB >> 24020590

Serum levels of albumin-amyloid beta complexes are decreased in Alzheimer's disease.

Keiichi Yamamoto1, Hiroyuki Shimada, Hideo Koh, Suzuka Ataka, Takami Miki.   

Abstract

AIM: Decreased amyloid β (Aβ) clearance from the brain to blood might play a key role in the development of Alzheimer's disease (AD). Aβ is normally bound to and transported by albumin in blood, thus possibly maintaining constant concentration of free Aβ in the blood. We therefore hypothesized that decreased blood levels of albumin-Aβ complexes could be associated with decreased Aβ removal from the brain to blood, resulting in Aβ accumulation in the brain.
METHODS: We carried out a cross-sectional investigation of the association between serum levels of albumin-Aβ complexes (SLAAC) and AD prevalence in 89 patients who visited our outpatient clinic, and gave written informed consent between August 2008 and May 2012.
RESULTS: We confirmed 45 cases of AD. Low SLAAC was associated with an increased prevalence of AD (OR 0.27; 95% CI 0.14-0.51) in a univariable logistic model and multivariable logistic models. In addition, decreased SLAAC was associated with decreased levels of Aβ42 in CSF (r = 0.38, P = 0.0221) and increased levels of p-tau in CSF (r = -0.43, P = 0.0090), findings that have been shown to be associated with AD progression.
CONCLUSIONS: This novel method might be very useful for monitoring of the progression of AD.
© 2013 Japan Geriatrics Society.

Entities:  

Keywords:  Alzheimer's disease; albumin; amyloid β; biomarkers; serum

Mesh:

Substances:

Year:  2013        PMID: 24020590     DOI: 10.1111/ggi.12147

Source DB:  PubMed          Journal:  Geriatr Gerontol Int        ISSN: 1447-0594            Impact factor:   2.730


  11 in total

1.  Fatty Acids Compete with Aβ in Binding to Serum Albumin by Quenching Its Conformational Flexibility.

Authors:  Cong Guo; Huan-Xiang Zhou
Journal:  Biophys J       Date:  2018-12-06       Impact factor: 4.033

Review 2.  Ultrasound treatment of neurological diseases--current and emerging applications.

Authors:  Gerhard Leinenga; Christian Langton; Rebecca Nisbet; Jürgen Götz
Journal:  Nat Rev Neurol       Date:  2016-02-19       Impact factor: 42.937

3.  Transthyretin stability is critical in assisting beta amyloid clearance- Relevance of transthyretin stabilization in Alzheimer's disease.

Authors:  Mobina Alemi; Sara C Silva; Isabel Santana; Isabel Cardoso
Journal:  CNS Neurosci Ther       Date:  2017-06-01       Impact factor: 5.243

4.  7,8-Dihydroxycoumarin Alleviates Synaptic Loss by Activated PI3K-Akt-CREB-BDNF Signaling in Alzheimer's Disease Model Mice.

Authors:  Li Yan; Yufan Jin; Junping Pan; Xiang He; Shiqian Zhong; Rongcai Zhang; LokLam Choi; Weiwei Su; Jiaxu Chen
Journal:  J Agric Food Chem       Date:  2022-06-03       Impact factor: 5.895

5.  Non-chaperone proteins can inhibit aggregation and cytotoxicity of Alzheimer amyloid β peptide.

Authors:  Jinghui Luo; Sebastian K T S Wärmländer; Astrid Gräslund; Jan Pieter Abrahams
Journal:  J Biol Chem       Date:  2014-08-06       Impact factor: 5.157

6.  Human Plasma Protein Corona of Aβ Amyloid and Its Impact on Islet Amyloid Polypeptide Cross-Seeding.

Authors:  Aparna Nandakumar; Yanting Xing; Ritchlynn R Aranha; Ava Faridi; Aleksandr Kakinen; Ibrahim Javed; Kairi Koppel; Emily H Pilkington; Anthony Wayne Purcell; Thomas P Davis; Pouya Faridi; Feng Ding; Pu Chun Ke
Journal:  Biomacromolecules       Date:  2020-01-21       Impact factor: 6.988

Review 7.  Extracellular protein components of amyloid plaques and their roles in Alzheimer's disease pathology.

Authors:  M Mahafuzur Rahman; Christofer Lendel
Journal:  Mol Neurodegener       Date:  2021-08-28       Impact factor: 14.195

Review 8.  Neuronal response in Alzheimer's and Parkinson's disease: the effect of toxic proteins on intracellular pathways.

Authors:  Shohreh Majd; John H Power; Hugh J M Grantham
Journal:  BMC Neurosci       Date:  2015-10-23       Impact factor: 3.288

9.  A multicenter, randomized, placebo-controlled trial for cilostazol in patients with mild cognitive impairment: The COMCID study protocol.

Authors:  Satoshi Saito; Shinsuke Kojima; Naoya Oishi; Ryosuke Kakuta; Takakuni Maki; Fumihiko Yasuno; Kazuyuki Nagatsuka; Haruko Yamamoto; Hidenao Fukuyama; Masanori Fukushima; Masafumi Ihara
Journal:  Alzheimers Dement (N Y)       Date:  2016-10-27

10.  Perspective: Is therapeutic plasma exchange a viable option for treating Alzheimer's disease?

Authors:  Bruno P Imbimbo; Stefania Ippati; Ferdinando Ceravolo; Mark Watling
Journal:  Alzheimers Dement (N Y)       Date:  2020-03-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.